DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Han E, Lee YH, Lee BW, Kang ES, Cha BS.
Ipragliflozin additively ameliorates non-alcoholic fatty liver disease in patients with type 2 diabetes controlled with metformin and pioglitazone: a 24-week randomized controlled trial.
J Clin Med 2020;
9 (01) E259
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.